Neurology 2001;56:323-327
© 2001 American Academy of Neurology
Articles
A controlled study of intravenous immunoglobulin combined with prednisone in the treatment of IBM
M. C. Dalakas, MD;,
B. Koffman, MD;,
M. Fujii, MD;,
S. Spector, MD;,
K. Sivakumar, MD; and
E. Cupler, MD
From the Neuromuscular Diseases Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD.
Address correspondence and reprint request to Dr. Marinos C. Dalakas, Chief, Neuromuscular Diseases Section, NINDS, NIH, Building 10, Room 4N248, 10 Center Dr. MSC 1382, Bethesda, MD 20892-1382.
OBJECTIVE: To investigate whether the combination of intravenous immunoglobulin (IVIg) with prednisone improves muscle strength and alters endomysial inflammation in patients with sporadic inclusion body myositis (s-IBM).
BACKGROUND: In a previous controlled trial in s-IBM, IVIg did not significantly improve strength in spite of modest benefits in some muscle groups. The possibility that prednisone may have a synergistic effect with IVIg prompted another controlled trial.
METHODS: Thirty-six patients with biopsy-proven IBM were randomized to receive IVIg or placebo monthly for 3 months. Before infusions, all patients were started on high-dose prednisone for 3 months. Primary outcome measures were differences in the 1) Quantitative Muscle Strength (QMT) testing; and 2) modified Medical Research Council (MRC) scores, between the patients randomized to IVIg + prednisone compared with those randomized to placebo + prednisone. Repeated open muscle biopsies were performed at random in 24 patients to determine changes in the number of autoinvasive T cells and necrotic muscle fibers.
RESULTS: Nineteen patients were randomized to IVIg + prednisone and 17 to placebo + prednisone. No significant change was noted in muscle strength, assessed by QMT and MRC, from baseline to the 2nd, 3rd, or 4th month after treatment between the two groups. The number of necrotic fibers was reduced in the IVIg randomized group (p < 0.01), and the mean number of CD2+ cells was significantly decreased in both groups (p < 0.0001), denoting a steroid effect.
CONCLUSION: IVIg combined with prednisone for a 3-month period was not effective in IBM. Endomysial inflammation was significantly reduced after treatment, but the reduction was not of clinical significance.
This article has been cited by other articles:
|
|
|
|
 
A A Amato and R J Barohn
Inclusion body myositis: old and new concepts
J. Neurol. Neurosurg. Psychiatry,
November 1, 2009;
80(11):
1186 - 1193.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A A Amato and R J Barohn
Evaluation and treatment of inflammatory myopathies
J. Neurol. Neurosurg. Psychiatry,
October 1, 2009;
80(10):
1060 - 1068.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. A Greenberg
How citation distortions create unfounded authority: analysis of a citation network
BMJ,
July 23, 2009;
339(jul20_3):
b2680 - b2680.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. C. Dalakas, G. Rakocevic, J. Schmidt, M. Salajegheh, B. McElroy, M. O. Harris-Love, J. A. Shrader, E. W. Levy, J. Dambrosia, R. L. Kampen, et al.
Effect of Alemtuzumab (CAMPATH 1-H) in patients with inclusion-body myositis
Brain,
June 1, 2009;
132(6):
1536 - 1544.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Kitazawa, V. Vasilevko, D. H. Cribbs, and F. M. LaFerla
Immunization with Amyloid-{beta} Attenuates Inclusion Body Myositis-Like Myopathology and Motor Impairment in a Transgenic Mouse Model
J. Neurosci.,
May 13, 2009;
29(19):
6132 - 6141.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Stangel
Review: New advances in the treatment of neurological diseases using high dose intravenous immunoglobulins
Therapeutic Advances in Neurological Disorders,
September 1, 2008;
1(2):
115 - 124.
[Abstract]
[PDF]
|
|
|
|
|
|
|
S. A. Greenberg
Proposed immunologic models of the inflammatory myopathies and potential therapeutic implications
Neurology,
November 20, 2007;
69(21):
2008 - 2019.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. B. Helmers, M. Dastmalchi, H. Alexanderson, I. Nennesmo, M. Esbjornsson, B. Lindvall, and I. E Lundberg
Limited effects of high-dose intravenous immunoglobulin (IVIG) treatment on molecular expression in muscle tissue of patients with inflammatory myopathies
Ann Rheum Dis,
October 1, 2007;
66(10):
1276 - 1283.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. M Gurcan and A R. Ahmed
Efficacy of Various Intravenous Immunoglobulin Therapy Protocols in Autoimmune and Chronic Inflammatory Disorders
Ann. Pharmacother.,
May 1, 2007;
41(5):
812 - 823.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Dimitri, O. Benveniste, O. Dubourg, T. Maisonobe, B. Eymard, Z. Amoura, L. Jean, K. Tiev, J.-C. Piette, D. Klatzmann, et al.
Shared blood and muscle CD8+ T-cell expansions in inclusion body myositis
Brain,
April 1, 2006;
129(4):
986 - 995.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. J. Barohn, L. Herbelin, J. T. Kissel, W. King, A. L. McVey, D. S. Saperstein, and J. R. Mendell
Pilot trial of etanercept in the treatment of inclusion-body myositis
Neurology,
January 24, 2006;
66(1_suppl_1):
S123 - S124.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Raju and M. C. Dalakas
Gene expression profile in the muscles of patients with inflammatory myopathies: effect of therapy with IVIg and biological validation of clinically relevant genes
Brain,
August 1, 2005;
128(8):
1887 - 1896.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B Ranque-Francois, T Maisonobe, E Dion, J-C Piette, M-P Chauveheid, Z Amoura, and T Papo
Familial inflammatory inclusion body myositis
Ann Rheum Dis,
April 1, 2005;
64(4):
634 - 637.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. C. Dalakas
Intravenous Immunoglobulin in Autoimmune Neuromuscular Diseases
JAMA,
May 19, 2004;
291(19):
2367 - 2375.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Schmidt, G. Rakocevic, R. Raju, and M. C. Dalakas
Upregulated inducible co-stimulator (ICOS) and ICOS-ligand in inclusion body myositis muscle: significance for CD8+ T cell cytotoxicity
Brain,
May 1, 2004;
127(5):
1182 - 1190.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Lindberg, E. Trysberg, A. Tarkowski, and A. Oldfors
Anti-T-lymphocyte globulin treatment in inclusion body myositis: A randomized pilot study
Neurology,
July 22, 2003;
61(2):
260 - 262.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Hilton-Jones
DIAGNOSIS AND TREATMENT OF INFLAMMATORY MUSCLE DISEASES
J. Neurol. Neurosurg. Psychiatry,
June 1, 2003;
74(90002):
ii25 - 31.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. B. Rutkove, R. A. Parker, R. A. Nardin, C. E. Connolly, K. J. Felice, and E. M. Raynor
A pilot randomized trial of oxandrolone in inclusion body myositis
Neurology,
April 9, 2002;
58(7):
1081 - 1087.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C M Wiles, P Brown, H Chapel, R Guerrini, R A C Hughes, T D Martin, P McCrone, J Newsom-Davis, J Palace, J H Rees, et al.
Intravenous immunoglobulin in neurological disease: a specialist review
J. Neurol. Neurosurg. Psychiatry,
April 1, 2002;
72(4):
440 - 448.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Cherin, S. Pelletier, A. Teixeira, P. Laforet, A. Simon, S. Herson, and B. Eymard
Intravenous immunoglobulin for dysphagia of inclusion body myositis
Neurology,
January 22, 2002;
58(2):
326 - 326.
[Full Text]
[PDF]
|
|
|
|
